Crohn's & colitis 360
Cure8 research brief
Why This Matters
This large real-world study provides evidence about how often patients with isolated proctitis need to escalate therapy after 5‑ASA or thiopurines and compares persistence/response across biologic classes — information that may help set expectations and inform future trials.
Who Should Pay Attention
Clinicians, researchers, adult patients with isolated proctitis or distal UC, and patients treated with 5‑ASA, thiopurines, anti‑TNF or anti‑integrin biologics.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This paper reports a large retrospective cohort analysis (NIHR IBD BioResource) of 8,346 patients with isolated proctitis (a form of ulcerative colitis) that measured real-world treatment escalation and persistence for common medical therapies.
Key reported findings in the abstract: treatment-escalation probabilities over 1–5 years after starting 5-ASA and thiopurines; older age at onset and longer disease duration were linked with lower escalation risk while extra‑intestinal manifestations increased escalation risk; among biologics evaluated, anti‑integrin therapy showed higher persistence/response versus some anti‑TNF agents in this cohort.
This is an observational, registry-based analysis of treatment patterns and associations rather than a randomized trial. The abstract concludes that randomized trials in isolated proctitis are still needed.
Keep In Mind
Results come from a retrospective registry (NIHR IBD BioResource). The abstract-level summary reports associations and odds/risk estimates; randomized trials are still needed to confirm comparative effectiveness.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationCrohn's & colitis 360
AuthorsYan K, Vuyyuru SK, Radford S +4 more
Study typeJournal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedOct 23, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Comparing real-world continuous clinical remission rates of anti-tumor necrosis factor, vedolizumab, ustekinumab, tofacitinib, and upadacitinib in ulcerative colitis
This large real‑world comparison helps show how different advanced therapies performed over 1 year in routine practice, highlighting that ustekinumab had strong outcomes overall while upadacitinib was most effective in...
Comparative efficacy and safety of subcutaneous vedolizumab versus other targeted inflammatory bowel therapies in patients with moderate to severe ulcerative colitis: a network meta-analysis update
This study compares many targeted IBD drugs indirectly to help clarify how subcutaneous vedolizumab stacks up against other biologics and newer oral therapies — information that could inform treatment discussions for...
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Adherence to advanced therapies in inflammatory bowel diseases: Real-world rates and predictors of non-adherence.
Adherence affects how well advanced IBD treatments work. Knowing which drug forms and patient factors link to missed doses can help patients and clinicians plan support strategies.